Roivant Sciences Ltd. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Frank Torti, President and Vant Chair of Roivant Sciences Inc., entered into an amended employment agreement effective July 28, 2025. Key terms: base salary $725,000 annually; one-time cash award of $7.5 million; 1,836,547 RSUs vesting over 5 years (20% on March 31, 2026, remainder quarterly); 11,900,000 performance-based RSUs; equity grants in subsidiary 'Vants' he chairs, with anti-dilution provisions. Severance is 1x base salary plus target bonus (100% of base) if terminated without cause or resignation for good reason. Many specific terms redacted as 'not material' and competitively sensitive.
Why this rating
One executive's employment amendment with ~$7.5M cash + substantial equity (~13.7M shares at public company level) is routine corporate governance for a $9.8B company. No strategic shift, material deal, or operational change disclosed.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.